Keratitis sicca (dry eye) - Symptoms, Causes, Treatment & Prevention

📅 Updated: May 2026 ⏱ 7 min read ✅ Medically reviewed
```html Keratitis sicca (dry eye) – Complete Medical Guide

Keratitis sicca (Dry Eye) – A Comprehensive Medical Guide

Overview

Keratitis sicca, commonly known as dry eye disease (DED), is a chronic condition in which the eyes do not produce enough tears, or the tears that are produced evaporate too quickly. The resulting imbalance leads to inflammation of the ocular surface and damage to the cornea (the clear front part of the eye).

Dry eye can affect anyone, but it is most prevalent in:

  • Women, especially after menopause (up to 3‑times higher risk than men).
  • Adults over 50 – prevalence rises from ~5% in those 20‑30 years old to >30% in people >70 years.1
  • Contact‑lens wearers, people who use digital screens >4 hours/day, and those with certain systemic diseases (e.g., Sjögren’s syndrome, rheumatoid arthritis).

According to the National Eye Institute, about 16 million Americans (≈7% of the population) experience symptomatic dry eye, and the numbers are climbing worldwide as screen use and aging populations increase.2

Symptoms

Symptoms can be intermittent or constant and may range from mild irritation to severe pain. Common complaints include:

  • Foreign‑body sensation – feeling like sand or a grit in the eye.
  • Burning or stinging – especially after waking or prolonged visual tasks.
  • Redness – due to ocular surface inflammation.
  • Excessive tearing – paradoxically, the eye may produce reflex tears that are watery but lack lubrication.
  • Blurry vision that improves with blinking.
  • Light sensitivity (photophobia).
  • Difficulty wearing contact lenses or intolerance to them.
  • Eye fatigue after reading, computer work, or driving.
  • Difficulty sleeping because the eyes feel uncomfortable when closed.

Symptoms often worsen in low‑humidity environments, windy conditions, air‑conditioned rooms, or after prolonged visual concentration.

Causes and Risk Factors

Primary mechanisms

  1. Reduced tear production – Damage to the lacrimal glands (e.g., autoimmune disease, aging) decreases aqueous tear volume.
  2. Increased tear evaporation – Meibomian gland dysfunction (MGD) leads to a deficient oily layer, allowing tears to evaporate quickly.
  3. Altered tear composition – Inflammation can change the mucin layer, reducing tear stability.
  4. Neurogenic factors – Reduced corneal sensitivity (often after ocular surgery) can lower the blink reflex, worsening dryness.

Risk factors

  • Age > 50 years
  • Female sex, especially post‑menopause
  • Autoimmune diseases: Sjögren’s syndrome, rheumatoid arthritis, lupus, thyroid eye disease
  • Medications that decrease tear production: antihistamines, antidepressants, beta‑blockers, isotretinoin, diuretics
  • Contact lens wear (especially extended wear)
  • Refractive surgery (LASIK, PRK) – can temporarily reduce corneal sensation
  • Environmental exposure: wind, smoke, low humidity, air‑conditioning, heated indoor spaces
  • Digital device use – reduced blink rate (up to 60% less than normal)
  • Blepharitis or eyelid malposition (e.g., entropion, ectropion)

Diagnosis

Diagnosing dry eye involves a combination of patient history, symptom questionnaires, and objective clinical tests.

Clinical interview & questionnaires

  • Ocular Surface Disease Index (OSDI) – a validated 12‑question survey that quantifies symptom severity.
  • History of systemic diseases, medication use, lifestyle factors, and previous eye surgeries.

Key diagnostic tests

  1. Schirmer test – A thin strip of filter paper is placed under the lower eyelid for 5 minutes; less than 5 mm of wetting indicates severe aqueous deficiency.
  2. Tear breakup time (TBUT) – Fluorescein dye is instilled, and the time until the first dry spot appears is measured; <10 seconds is abnormal.
  3. Ocular surface staining – Fluorescein, lissamine green, or rose bengal highlight damaged epithelial cells; staining patterns help grade severity.
  4. Meibomian gland evaluation – Expressibility and quality of oil are assessed; blockage or atrophy points to MGD.
  5. Osmolarity testing – Tear film osmolarity >308 mOsm/L is a biomarker for dry eye.
  6. Inflammatory markers – In‑office interferometry or laboratory assays for matrix metalloproteinase‑9 (MMP‑9) can document ocular surface inflammation.
  7. Imaging – Meibography (infrared imaging) visualizes gland morphology.

Because dry eye is multifactorial, clinicians often use a combination of these tests to classify the disease as aqueous‑deficient, evaporative, or mixed.

Treatment Options

Treatment follows a stepwise approach, starting with the least invasive measures and progressing to prescription medications or procedures as needed.

1. Lifestyle & environmental modifications

  • Take a 20‑second break every 20 minutes during screen work (the “20‑20‑20 rule”).
  • Use a humidifier to keep indoor humidity between 40–60%.
  • Avoid direct airflow from fans, air‑conditioners, or heaters.
  • Wear wrap‑around sunglasses outdoors to reduce wind exposure.
  • Stay hydrated (≈2 L water/day) and maintain a balanced diet rich in omega‑3 fatty acids.

2. Over‑the‑counter (OTC) lubricants

  • Artificial tears – preservative‑free formulas are preferred for frequent use; gels or ointments provide longer residence time for nighttime relief.
  • Lipids‑containing drops (e.g., Systane Balance, Refresh Optive) help restore the tear film’s oily layer.
  • Apply 4–6 times daily, or more often with prolonged visual tasks.

3. Prescription medications

  1. Cycloplegic anti‑inflammatories
    • Cyclosporine ophthalmic emulsion 0.05% (Restasis) – improves tear production by reducing ocular surface inflammation; benefits often appear after 3–6 months.
    • Lifitegrast 5% (Xiidra) – blocks the interaction between LFA‑1 and ICAM‑1, reducing inflammation; may work faster (4‑6 weeks).
  2. Short‑course corticosteroid drops (e.g., loteprednol, prednisolone acetate) – used for acute inflammation under close supervision, typically ≀2 weeks.
  3. Secretagogues – oral agents such as pilocarpine or cevimeline stimulate tear secretion in severe aqueous‑deficient disease.

4. Procedural interventions

  • Punctal plugs – tiny silicone or collagen plugs inserted into the tear drainage ducts to retain tears; reversible and often first‑line for moderate disease.
  • Thermal eyelid cleaning (Lipiflow, iLUMI) – applies controlled heat and pressure to unblock meibomian glands.
  • Meibomian gland expression – manual expression performed by an eye‑care professional.
  • Intense pulsed light (IPL) – reduces inflammation and improves gland function, especially in refractory MGD.
  • Autologous serum eye drops – for severe ocular surface disease; contain growth factors mirroring natural tears.
  • Amniotic membrane grafts** or **scleral lenses** (e.g., PROSE) – for cases with corneal ulceration or persistent epithelial defects.

5. Nutritional supplementation

Omega‑3 fatty acids (EPA/DHA) 1–2 g/day have shown moderate benefit in reducing tear evaporation and inflammation (supported by randomized trials and the American Academy of Ophthalmology).3

Living with Keratitis sicca (dry eye)

Daily management checklist

  • Apply preservative‑free artificial tears before and after screen time.
  • Use lid hygiene: warm compresses (5‑10 min) followed by gentle eyelid massage twice daily.
  • Insert punctal plugs as instructed; clean the surrounding eye area with sterile saline.
  • Keep a symptom diary to track triggers (e.g., wind, specific medications).
  • Schedule regular follow‑ups (every 6–12 months) to reassess tear film tests and adjust therapy.
  • Wear protective eyewear when outdoors (UV‑blocking sunglasses).
  • Limit caffeine and alcohol, which can exacerbate dehydration.
  • Consider low‑light reading glasses with anti‑reflective coating to reduce glare.

Work‑place accommodations

Ask employers for:

  • Frequent short breaks (micro‑breaks) for blinking.
  • Adjustable monitor height to keep the screen slightly below eye level, encouraging full eyelid closure.
  • Humidified office spaces or desk‑mounted humidifiers.

Prevention

While some risk factors (age, genetics) cannot be changed, many strategies can lower the chance of developing or worsening dry eye:

  • Maintain adequate hydration and a diet rich in omega‑3s (fatty fish, flaxseed, walnuts).
  • Practice good eyelid hygiene from an early age to prevent blepharitis.
  • Limit exposure to smoke, pollutants, and harsh chemicals.
  • Use preservative‑free eye drops if you need frequent lubrication.
  • Discuss medication side‑effects with your prescriber; alternatives may exist for antihistamines or diuretics.
  • Schedule routine eye exams, especially after menopause or if you have an autoimmune condition.

Complications

If left untreated, chronic keratitis sicca can lead to serious ocular problems:

  • Corneal epithelial breakdown – recurrent erosions or ulcerations, increasing infection risk.
  • Scar formation – may cause permanent visual distortion.
  • Infection – bacterial, viral, or fungal keratitis becomes more likely on a compromised surface.
  • Reduced quality of life – chronic pain, visual fatigue, and depression are reported in up to 30% of severe cases.4
  • Contact‑lens intolerance – many patients are forced to discontinue lens wear.
  • Secondary glaucoma – chronic inflammation can raise intra‑ocular pressure in rare cases.

When to Seek Emergency Care

Call 911 or go to the nearest emergency department if you experience any of the following:
  • Sudden, severe eye pain that does not improve with lubricants.
  • Rapid vision loss or a sudden clouding of vision.
  • Bright, flashing lights or a curtain‑like shadow across the visual field (possible retinal detachment).
  • Signs of infection: intense redness, pus, swelling, fever, or a gritty sensation that worsens.
  • Corneal ulcer or white spot on the cornea observed by a clinician.
These symptoms may indicate an acute corneal infection, ulcer, or other sight‑threatening condition that requires immediate treatment.

References

  1. American Academy of Ophthalmology. “Dry Eye.” AAO Preferred Practice Pattern, 2023.
  2. National Eye Institute. “Dry Eye Disease.” NEI Factsheet, 2022. https://www.nei.nih.gov/learn-about-eye-health/eye-conditions-and-diseases/dry-eye-disease
  3. Wagner, T. et al. “Effect of Omega‑3 Supplements on Dry Eye Disease: A Systematic Review.” *Ophthalmology* 2021;128(5):714‑724.
  4. Bron, A.J., de Paiva, C.S. “The Impact of Dry Eye on Quality of Life.” *Clinical Ophthalmology* 2020;14:1249‑1261.
  5. U.S. Centers for Disease Control and Prevention. “Sjogren’s Syndrome and Dry Eye.” CDC, 2023.
```

⚠ Medical Disclaimer

Important: The information provided on this page is for general informational purposes only and is not intended as a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition.

If you think you may have a medical emergency, call your doctor, go to the emergency department, or call 911 immediately.

📚 Medical References